Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

KRAS K104 modification affects KRASG12D-GEF interaction and mediated cell growth and motility

ABSTRACT: Mutant RAS genes play an important role in regulating tumors through lysine residue 104 to impair GEF-induced nucleotide exchange, but the regulatory role of KRAS K104 modification on the KRASG12D mutant is not yet clear. We found that KRASG12D/K104Q decreased the bind to RBD of Raf1 and also decreased cell growth, invasion and migration as well as whole-genome cDNA microarray found that KRASG12D/K104Q decrease the expression of NPIPA2, DUSP1 and IL6 in lung and ovarian cancer cells. This study clear implicates computational and experimental studies involving Lys104 of KRASG12D and GEF and provides a target for the analysis of future treatments.

ORGANISM(S): Homo sapiens

PROVIDER: GSE158235 | GEO | 2020/09/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

KRAS K104 modification affects KRASG12D-GEF interaction and mediated cell growth and motility

Project description:KRAS K104 modification affects KRASG12D-GEF interaction and mediated cell growth and motility

| PRJNA664398 | ENA

Hypoxia inhibits HUNK-mediated phosphorylation of GEF-H1 for epithelial-to-mesenchymal transition

Project description:Hypoxia regulates epithelial to mesenchymal transition (EMT) of cancer cells. However, the mechanism underlying hypoxia-mediated EMT remains largely unknow. Here, utilizing colorectal cell carcinoma (CRC) as a model, we find that HUNK inhibits EMT and suppresses metastasis of CRC cells via its substrate GEF-H1 in a kinase-dependent manner. Mechanistically, HUNK directly phosphorylates GEF-H1 at ser645 site, which activates RhoA and consequently leads to a cascade of phosphorylation of LIMK1/CFL-1, thereby stabilizing F-actin and inhibiting EMT. Moreover, hypoxia suppresses HUNK activity and dephosphorylates GEF-H1 to promote EMT. Clinically, the expression levels of both HUNK and phosphorylation of GEH-H1 ser645 are not only downregulated in CRC tissues with metastasis compared to that without metastasis, but also positively correlated among these tissues. Our findings highlight the importance of hypoxia-regulated HUNK kinase activity and phosphorylation of GEF-H1 in regulation of EMT and metastasis of CRC.

2022-05-27 | GSE203440 | GEO

GEF-H1 mediated gene expression changes in BMDCs in response to microtubule destabilization

Project description:GEF-H1 controls transcriptional programs that mediate antitumor immuity upon microtubule destabilization.

2019-10-01 | GSE135264 | GEO

Transcription profiling of pancreata from wild type, KrasG12D, Ela-Tgfa and KrasG12D Ela-Tgfa mice

Project description:Transcription profiling by array of pancreas from KrasG12D, Ela-Tgfa and KrasG12D Ela-Tgfa mice

2008-07-23 | E-TABM-304 | biostudies-arrayexpress

RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

Project description:Experiment designed to study the effect of 1 or 2 copies of deregulated myc on transcriptional profile during pancreatic cancer progression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ mice treated 12 hours with Tamoxifen.

2022-06-08 | E-MTAB-10807 | biostudies-arrayexpress

Comparison of KrasG12D/WT;p53Fx/Fx and KrasG12D/G12D;p53Fx/Fx MEFs

Project description:Microarray expression data generated to compare the biological impact of KrasG12D allelic duplication in p53null mouse embryonic fibroblasts (MEFs). The RAS/MAPK-signalling pathway is frequently deregulated in non-small cell lung cancer (NSCLC), often through activating mutations in KRAS. Mouse models demonstrated that activation of a single endogenous mutant Kras allele is sufficient to promote lung tumour formation, but acquisition of other genetic alterations is required for malignant progression. Using a well-established lung cancer mouse model we recently demonstrated that advanced KrasG12D-driven spontaneous tumours frequently exhibit enhanced MAPK signalling and KrasG12D allelic enrichment (KrasG12D/Kraswild-type>1), implying that mutant Kras copy gains are positively selected during lung cancer progression. To compare the oncogenic impact of a single mutant allele versus additional mutant Kras copy gain, we carried out a comprehensive analysis of mutant Kras homozygous and heterozygous MEFs and lung cancer cells and show that these genotypes are phenotypically distinct. Title: Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities Authors: Emma M Kerr, Edoardo Gaude, Frances K Turrell, Christian Frezza and Carla P Martins

2016-02-24 | GSE75871 | GEO

GEF-H1-IRF5 mediated gene expression changes in BMDM by MDP recognition

Project description:The transcription factor IRF5 is essential for immune defense against pathogens. Here, the authors show that the microtubule-associated factor GEF-H1 plays a critical role in host defense against Listeria monocytogenes in macrophages via activation of the IRF5 kinase IKKe

2019-04-02 | GSE126749 | GEO

Comparison of gene expression changes of pancreatic tissue from Ptf1aCre;KrasG12D and Ptf1aCre;KrasG12D;SnailKI/+ mice

Project description:Comparison of gene expression changes of pancreatic tissue from Ptf1aCre;KrasG12D and Ptf1aCre;KrasG12D;SnailKI/+ mice at the age of 1 month and 3 months.

2022-11-19 | E-MTAB-8174 | biostudies-arrayexpress

Next Generation Sequencing Facilitates Quantitative Analysis of pancreatic tissue transcriptomes from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein

Project description:Purpose: we used next generation sequencing to analyze gene expression profiles of pancreatic tissues from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein. The goals of this study are to compare the different gene expression profiles of pancreatic tissue between KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein.

2021-06-11 | GSE176571 | GEO

Expression arrays of KRASG12D rhabdomyosarcoma models in zebrafish

Project description:Rhabdomyosarcoma is a pediatric malignancy thought to arise from the uncontrolled proliferation of myogenic cells. Here, we have generated models of rhabdomyosarcoma in the zebrafish by inducing oncogenic KRASG12D expression at different stages during muscle development. Several zebrafish promoters were used including the cdh15 and rag2 promoters that drive gene expression in early muscle progenitors, and the mylz2 promoter that expresses in differentiating myoblasts. The tumors that developed differed in their ability to recapitulate normal myogenesis. cdh15:KRASG12D and rag2:KRASG12D fish developed tumors that displayed an inability to fully undergo muscle differentiation by histologic appearance and gene expression analyses. In contrast, mylz2:KRASG12D tumors more closely resembled mature skeletal muscle and were most similar to well-differentiated human rhabdomyosarcoma by gene expression. mylz2:KRASG12D fish showed significantly improved survival compared to cdh15:KRASG12D and rag2:KRASG12D fish. Tumor-propagating activity was enriched in myf5-expressing cell populations within all of the tumor types. Our results demonstrate that oncogene expression at different stages during muscle development has profound effects on the ability of tumor cells to recapitulate normal myogenesis, altering the tumorigenic capability of these cells.

2013-07-17 | GSE39731 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data